STOCK TITAN

Veradermics, Incorporated (MANE) S-1 Filings

MANE NYSE

Here are the S-1 registration statements from Veradermics, Incorporated (MANE) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

An S-1 covers the registration statement a company files to sell shares publicly, so if you follow MANE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MANE filings page.

Rhea-AI Summary

Veradermics, Incorporated filed a resale registration covering up to 16,772,058 shares of common stock and up to 300,000 shares issuable upon exercise of pre-funded warrants. All registered shares may be sold from time to time by existing selling stockholders; Veradermics is not selling shares and will not receive proceeds from these resales, other than potential cash from warrant exercises at an exercise price of $0.00001 per share.

The Resale Shares represent approximately 40.6% of the 41,780,136 shares of common stock outstanding as of June 30, 2026, which could materially expand tradable float. Veradermics is a dermatologist‑founded, late clinical‑stage biopharmaceutical company focused on pattern hair loss, led by oral extended‑release minoxidil candidate VDPHL01, and qualifies as an emerging growth and smaller reporting company using reduced disclosure.

Rhea-AI Summary

Veradermics is registering 3,350,000 shares of common stock or pre-funded warrants in a primary offering, alongside a concurrent private placement (PIPE), with the aggregate securities issued across both remaining 3,350,000. The company develops VDPHL01, an extended‑release oral minoxidil candidate for pattern hair loss in men and women. A Phase 2/3 trial in 519 men met all primary and key secondary endpoints, with VDPHL01 achieving 30.3 and 33.0 non‑vellus hairs/cm² increases versus 7.3 for placebo and high rates of patient‑reported improvement. Treatment was generally well tolerated without treatment‑related serious cardiac events. Veradermics estimates net proceeds of about $212.9 million from the offering and PIPE, assuming a $67.84 share price, and reported preliminary cash, cash equivalents and marketable securities of approximately $390.8 million as of March 31, 2026. Together, this capital is expected to fund operations into 2030, including commercialization preparation for VDPHL01 if approved.